NAVINFLUOR - Navin Fluorine International Limited Share Price

Chemicals & Petrochemicals

₹4512.40-9.20(-0.20%)

Market Closed as of May 2, 2025, 15:30 IST

What does Navin Fluorine International Limited do?

Specialty Chemicals•Chemicals•Small Cap

Navin Fluorine International Limited manufactures and sells specialty fluorochemicals in India and internationally. The company offers refrigerants for various applications, including window and split room air conditioners, chillers, packaged air conditioners, commercial and industrial refrigeration units, intermediate for active pharmaceutical ingredient, fluoropolymer resins, domestic and industrial refrigerators, and mobile air conditioning under the Mafron brand for original equipment manufacturer, service technicians, and equipment owners. It provides inorganic fluoride products, such as ammonium bifluoride, potassium fluoride, sodium fluoride, potassium fluorotitanate, potassium fluoroborate, hexafluorophosphoric acid, and hydrofluo pyridine and hydrofluo urea complex products for oil and gas, stainless steel, pharmaceutical and agrochemicals, abrasives, electronics, and solar energy industries. In addition, the company offers various specialty fluoro intermediates consisting of boron trifluoride gas and adducts for pharmaceutical industry, as well as crop protection, hydrocarbon, and fragrance applications; and contract development and contract manufacturing services comprising basic research, library syntheses, process development, scale up, and batch manufacturing for custom chemical syntheses of fluorinated compounds in the pharmaceuticals, agro chemicals, and specialty chemicals industries. Navin Fluorine International Limited was founded in 1967 and is headquartered in Mumbai, India.

Industry Group:Chemicals & Petrochemicals

Employees:1,487

Website:www.nfil.in

Summary of Latest Earnings Report from Navin Fluorine International

Summary of Navin Fluorine International's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Management Outlook and Major Points:

Outlook:

Resilient Growth: Management remains confident in navigating global uncertainties, highlighting resilience across verticals. The company aims to sustain EBITDA margins (~24-25%) through operational efficiency, cost discipline, and project execution.
Capacity Ramp-Up: The newly commissioned agro specialty plant (INR540 crore investment) has begun commercial dispatches, with full utilization expected over 2 years. The AHF project (INR450 crore) is on track for FY26 commissioning, enhancing captive use and external sales.
CDMO Momentum: Strong order visibility for CY25, with European CDMO registrations nearing completion. The cGMP4 facility (INR160 crore Phase 1) is slated for Q3 FY26 commissioning, supporting the $100 million CDMO revenue target by FY27.
HPP Expansion: R32 capacity expansion (4,500 MT) by Feb 2025; exploring further capacity enhancements with global partners.

Key Highlights:

Financial Performance: Q3 FY25 revenue crossed INR600 crore (21% YoY growth). EBITDA surged 95% YoY to INR147 crore (24.3% margin), driven by HPP realizations and specialty chemicals utilization.
Segment Growth:
- HPP: 22% YoY growth (INR306 crore) on higher R32/HFO demand.
- Specialty Chemicals: 26% YoY growth (INR221 crore) with strong FY25/26 order visibility. Two new molecules (agro-focused) to launch by Q1 FY26.
- CDMO: 8% YoY growth (INR79 crore); European direct dispatches started, U.S. scale-up order secured.
Sustainability: Dewas facility awarded EcoVadis Gold Medal.
Balance Sheet: Net debt-to-equity at 0.41; working capital days at 99.

Strategic Priorities: Focus on customer relationships, new acquisitions, and disciplined capex (INR1,200"“1,400 crore over 3 years) to drive long-term value.

Q&A Session

Last updated: Feb 25

Question 1 (Sanjesh Jain, ICICI Securities):
"On the Nectar project, we have started dispatches, but is the performance of the plant on the expected line in terms of yield, operation and all, and has it been running on the expected line there?"
Answer: The plant is ramping up progressively with a focus on safety and reliability. Commercial dispatches began in December 2023, but full utilization will take time due to complex chemistry. The ramp-up is expected to reach peak capacity over two years, with FY25 contributions being gradual and FY27 targeted for full revenue potential.

Question 2 (Sanjesh Jain, ICICI Securities):
"On CDMO, particularly on the Fermion product... Is it fair to assume that now with the registration probably completed soon, we should be scaling up? And when you say we have secured the order for CY '25, what is the quantum of order that we are talking about?"
Answer: Registration for the Fermion MSA contract is in advanced stages (expected April/May 2025), with direct dispatches already starting. CY25 orders are secured and expected to match or exceed current volumes. FY26 projections remain strong, with 30% of the $100M CDMO target (FY27) tied to this contract.

Question 3 (Sanjesh Jain, ICICI Securities):
"On Specialty Chemicals... Is the classification difference or there is a delivery difference? How should one read about it?"
Answer: Domestic vs. export classification reflects supply-chain logistics (delivery to local partners of global customers), not market demand. Capacity utilization at Dahej/Surat improved to ~85% in Q3 due to volume-driven strategies and process efficiencies.

Question 4 (Sanjesh Jain, ICICI Securities):
"Once the AHF plant starts, what is the savings that we could do as we are buying AHF now from the outside market?"
Answer: Captive AHF (25,000"“27,000 MT for internal use) reduces reliance on external purchases. Merchant sales (6,000"“7,000 MT) will improve margins. The project also enables entry into higher-value AHF applications (e.g., high-purity grades for EVs via collaborations).

Question 5 (Madhav Marda, FIL Industries):
"On the Specialty Chemical business... Are we seeing the cycle kind of turning finally after almost 6, 7 quarters of weakness?"
Answer: Agri-chemical demand fundamentals remain strong long-term (crop protection, biofuels). Near-term pricing pressures persist, but NFIL secured volumes via customer partnerships, process improvements, and new molecule launches (2 in Q4/Q1).

Question 6 (Madhav Marda, FIL Industries):
"On R32... How do you look at R32 pricing for us, domestic and export market?"
Answer: R32 demand remains constructive globally. Pricing is expected to rise due to tight supply-demand dynamics. NFIL's incremental R32 capacity (4,500 MT by Feb 2025) and discussions with global players for further expansion signal optimism.

Question 7 (Sudarshan Padmanabhan, JM Financial):
"On CDMO... Beyond the $100 million, are we in a sweet spot with late-stage products?"
Answer: CDMO's growth is diversified across ~35"“50 active molecules, with 8"“10 in commercial stages. The pipeline includes oncology/neurology therapies. cGMP4 Phase 1 (INR160cr) commissioning in Q3FY26 will support scalability, with land reserved for future expansions.

Question 8 (Rohit Nagraj, B&K Securities):
"On AHF... How many years will it take to fulfill captive capacity optimally?"
Answer: AHF is a strategic enabler for higher-value fluorochemicals. Captive demand will absorb most capacity, with merchant sales focused on premium segments. Realization/kg improvement is prioritized over volume timelines.

Question 9 (Ankur Periwal, Axis Capital):
"On Specialty Chemicals' new molecules... What is the revenue timeline?"
Answer: The INR540cr agro plant's peak revenue (INR515cr) is expected in FY27. Other projects (MPP, Orchid) will near peak utilization in FY26. Margin sustainability (24.3% in Q3) stems from operating leverage, procurement efficiencies, and fixed-cost control.

Question 10 (Jignesh Kamani, Nippon Mutual Funds):
"On Project Nectar's anchor client... Are approvals for new customers delayed?"
Answer: The anchor client's ramp-up is gradual (safety-first approach). FY25 revenue will be limited, with ~40-45% of peak expected in FY26. Qualification batches for 2-3 additional customers are underway, with FY27 commercialization targeted.

Question 11 (Nirav Jimudia, Anvil Research):
"On fluorspar supply risks... How is NFIL placed?"
Answer: Fluorspar sourcing is diversified (Mexico, China, Africa) via long-term contracts. The new AHF plant is designed to handle multiple ore types, mitigating supply risks. No disruptions are anticipated.

Question 12 (Keyur Pandya, ICICI Prudential):
"On cGMP3/cGMP4 revenue potential..."
Answer: cGMP3 peak revenue is ~$50-60M. cGMP4 Phase 1 (dedicated to Fermion) will ramp quickly, contributing significantly to FY27's $100M CDMO target. Employee costs stabilized at INR70-75cr/quarter post-ESOP adjustments.

Balance Sheet for Navin Fluorine International

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	44.9%	2	1.69	1.26	9.09	9.28	74
Current investments	-12%	398	452	315	31	269	102
Loans, current	-100.2%	0.61	234	179	180	54	299
Total current financial assets	-24.9%	770	1,025	792	631	650	834
Inventories	-10.7%	192	215	251	327	289	229
Current tax assets	-	0	0	71	0	0	0
Total current assets	-21.5%	1,004	1,279	1,115	1,021	980	1,100
Property, plant and equipment	1.1%	639	632	604	427	381	388
Capital work-in-progress	70.5%	76	45	44	154	62	26
Investment property	0%	39	39	39	40	40	41
Non-current investments	35.5%	951	702	704	705	704	517
Loans, non-current	-5.3%	0.21	0.25	0.41	0.32	3.92	2.88
Total non-current financial assets	34.6%	969	720	723	723	726	536
Total non-current assets	20.7%	1,756	1,455	1,434	1,381	1,249	1,024
Total assets	1%	2,760	2,734	2,550	2,403	2,229	2,124
Total non-current financial liabilities	-21.4%	12	15	15	9.37	10	12
Provisions, non-current	0%	17	17	15	13	13	13
Total non-current liabilities	-2.4%	82	84	61	54	54	56
Borrowings, current	23.1%	49	40	67	0	0	0
Total current financial liabilities	-11.5%	279	315	202	160	163	165
Provisions, current	-35.9%	6.77	10	10	6.36	5.42	4.83
Current tax liabilities	18.4%	0.6	0.51	8.37	8.22	13	9.24
Total current liabilities	-13%	302	347	242	208	197	204
Total liabilities	-11.1%	384	432	333	262	251	260
Equity share capital	0.1%	9.92	9.91	9.91	9.91	9.91	9.91
Total equity	3.3%	2,377	2,302	2,217	2,141	1,978	1,864
Total equity and liabilities	1%	2,760	2,734	2,550	2,403	2,229	2,124

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	42.6%	9.04	6.64	8.24	14	15	76
Current investments	-17.7%	400	486	446	31	269	104
Loans, current	-5.1%	0.59	0.61	0.21	0	0.8	0.51
Total current financial assets	-10.1%	940	1,045	824	635	679	564
Inventories	-3%	361	372	429	468	348	258
Total current assets	-8.4%	1,423	1,553	1,442	1,464	1,341	1,019
Property, plant and equipment	3.6%	1,797	1,734	1,663	1,505	922	415
Capital work-in-progress	12.3%	798	711	520	279	570	742
Investment property	-2%	50	51	51	52	52	53
Goodwill	0%	88	88	88	88	88	88
Non-current investments	-11.8%	7.22	8.05	11	12	11	13
Loans, non-current	-5.3%	0.21	0.25	0.41	0.32	0	0
Total non-current financial assets	-3.2%	31	32	55	40	61	32
Total non-current assets	6.8%	3,017	2,824	2,578	2,063	1,711	1,366
Total assets	1.5%	4,441	4,377	4,022	3,529	3,052	2,385
Borrowings, non-current	-8.2%	939	1,023	1,024	753	500	100
Total non-current financial liabilities	-8.4%	953	1,040	1,049	760	520	110
Provisions, non-current	11.8%	20	18	17	15	14	14
Total non-current liabilities	-7.4%	1,052	1,136	1,102	823	556	157
Borrowings, current	32.3%	419	317	214	96	94	4.47
Total current financial liabilities	8.8%	876	805	564	451	501	327
Provisions, current	-24.6%	9.29	12	11	7.96	6.33	5.4
Current tax liabilities	-72.7%	0.62	0.78	8.47	8.23	12	9.24
Total current liabilities	7.1%	919	858	625	521	551	384
Total liabilities	-1.2%	1,971	1,994	1,756	1,344	1,107	541
Equity share capital	0.1%	9.92	9.91	9.91	9.91	9.91	9.91
Total equity	3.7%	2,470	2,383	2,266	2,185	1,945	1,844
Total equity and liabilities	1.5%	4,441	4,377	4,022	3,529	3,052	2,385

Income Statement for Navin Fluorine International

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-12.7%	1,421	1,628	1,404	1,133	1,022	955
Other Income	65%	67	41	37	75	31	35
Total Income	-10.9%	1,488	1,669	1,441	1,208	1,054	990
Cost of Materials	-9.8%	651	722	646	520	488	441
Purchases of stock-in-trade	-	0	0	0	0	0	13
Employee Expense	3.5%	210	203	153	125	112	97
Finance costs	277.1%	4.96	2.05	1.66	1.42	1.6	0.47
Depreciation and Amortization	35.7%	58	43	44	41	34	26
Other expenses	7.3%	309	288	257	186	185	185
Total Expenses	-0.2%	1,248	1,251	1,094	864	797	763
Profit Before exceptional items and Tax	-42.7%	240	418	347	343	257	227
Exceptional items before tax	-	52	0	0	66	0	0
Total profit before tax	-30.2%	292	418	347	410	257	227
Current tax	-67.3%	35	105	81	119	-58.68	72
Deferred tax	11766.7%	22	0.82	-0.02	-8.3	-84.43	5.63
Total tax	-46.7%	57	106	81	110	-143.1	78
Total profit (loss) for period	-24.8%	235	312	266	299	400	148
Other comp. income net of taxes	-1072.7%	-1.58	0.78	-0.78	-0.05	-0.71	-0.32
Total Comprehensive Income	-25.3%	234	313	266	299	399	148
Earnings Per Share, Basic	-25.2%	47.44	63.05	53.79	60.46	80.83	30.05
Earnings Per Share, Diluted	-25%	47.37	62.83	53.76	60.37	80.75	30.03

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	14%	440	386	376	397	359	315
Other Income	-9.1%	11	12	20	15	14	26
Total Income	13.4%	451	398	396	412	373	341
Cost of Materials	24.7%	223	179	168	177	174	139
Employee Expense	-5.5%	53	56	57	58	54	39
Finance costs	-217.2%	0.66	1.29	0.69	1.3	0.64	1.42
Depreciation and Amortization	0%	17	17	17	16	16	14
Other expenses	12.2%	93	83	85	84	89	73
Total Expenses	10.3%	366	332	330	363	335	270
Profit Before exceptional items and Tax	29.2%	85	66	66	48	37	71
Exceptional items before tax	-	0	0	0	0	52	0
Total profit before tax	29.2%	85	66	66	48	90	71
Current tax	40%	22	16	16	-10.44	10	15
Deferred tax	-81.6%	-2.16	-0.74	-0.27	15	6.94	0.17
Total tax	26.7%	20	16	16	4.5	17	15
Total profit (loss) for period	30.6%	65	50	50	44	72	56
Other comp. income net of taxes	26.1%	0.12	-0.19	0.5	-0.47	0	0.21
Total Comprehensive Income	30.6%	65	50	51	44	72	56
Earnings Per Share, Basic	33.8%	13.16	10.09	10.09	8.88	14.56	11.3
Earnings Per Share, Diluted	33.8%	13.15	10.08	10.08	8.86	14.54	11.26

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-0.6%	2,065	2,077	1,453	1,179	1,062	996
Other Income	57.1%	56	36	39	79	33	34
Total Income	0.4%	2,121	2,113	1,493	1,258	1,095	1,030
Cost of Materials	-0.4%	902	906	650	528	496	461
Purchases of stock-in-trade	-55.6%	9.43	20	25	21	13	13
Employee Expense	14.9%	286	249	182	142	131	115
Finance costs	174.1%	75	28	1.9	1.84	2	0.83
Depreciation and Amortization	53.2%	96	63	48	44	37	28
Other expenses	16.5%	445	382	251	191	183	186
Total Expenses	13.6%	1,837	1,617	1,148	916	837	806
Profit Before exceptional items and Tax	-43%	283	496	344	342	258	224
Exceptional items before tax	-	52	0	0	16	0	0
Total profit before tax	-32.3%	336	496	344	358	258	224
Current tax	-66.7%	36	106	82	119	-58.09	73
Deferred tax	100%	29	15	-0.61	-8.63	-85.47	4.04
Total tax	-46.7%	65	121	81	111	-143.56	77
Total profit (loss) for period	-28.1%	270	375	263	258	409	149
Other comp. income net of taxes	-194.2%	0.02	2.04	-1.23	2.21	0.52	-1.19
Total Comprehensive Income	-28.2%	271	377	262	260	409	148
Earnings Per Share, Basic	-28.3%	54.57	75.7	53.12	52.03	82.6	30.17
Earnings Per Share, Diluted	-28.1%	54.49	75.44	53.08	51.96	82.53	30.15

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	16.8%	606	519	524	602	502	472
Other Income	-10%	10	11	10	13	12	23
Total Income	16.4%	617	530	534	614	514	495
Cost of Materials	23.1%	289	235	218	270	228	185
Purchases of stock-in-trade	-73.1%	1.18	1.67	2.11	1.45	2	2.39
Employee Expense	-7.9%	71	77	78	71	75	61
Finance costs	46.2%	20	14	16	17	18	20
Depreciation and Amortization	7.4%	30	28	27	26	25	24
Other expenses	12.8%	124	110	115	120	120	111
Total Expenses	12.4%	509	453	466	535	469	418
Profit Before exceptional items and Tax	40.8%	108	77	68	79	45	77
Exceptional items before tax	-	0	0	0	0	52	0
Total profit before tax	40.8%	108	77	68	79	97	77
Current tax	31.2%	22	17	16	-10.61	11	16
Deferred tax	662.5%	2.22	1.16	0.61	20	8.37	1.06
Total tax	35.3%	24	18	17	9.04	19	17
Total profit (loss) for period	43.1%	84	59	51	70	78	61
Other comp. income net of taxes	-465.5%	-1.12	1.58	0.63	-0.85	0.29	0.27
Total Comprehensive Income	37.3%	82	60	52	70	78	61
Earnings Per Share, Basic	46%	16.86	11.86	10.33	14.2	15.74	12.22
Earnings Per Share, Diluted	46%	16.84	11.85	10.32	14.18	15.71	12.18

Cash Flow for Navin Fluorine International

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	277.1%	4.96	2.05	1.66
Change in inventories	212.5%	112	-97.65	-75.14
Depreciation	35.7%	58	43	44
Unrealised forex losses/gains	-604.5%	-0.55	0.78	0.62
Share-based payments	-97.1%	1.47	17	0
Net Cashflows from Operations	119.3%	615	281	345
Dividends received	0%	-0.03	-0.03	-0.02
Interest received	-35.8%	-16.37	-11.79	-19.13
Income taxes paid (refund)	-68.2%	35	108	81
Other inflows (outflows) of cash	12.3%	-8.13	-9.41	-8.42
Net Cashflows From Operating Activities	267.5%	556	152	237
Cashflows used in obtaining control of subsidiaries	-100.5%	0	190	150
Proceeds from sales of PPE	4641.4%	56	2.16	3.05
Purchase of property, plant and equipment	-26.9%	142	194	61
Cash receipts from repayment of advances and loans made to other parties	-99.8%	1.71	452	0.75
Dividends received	0%	0.03	0.03	0.02
Interest received	84.9%	15	8.57	16
Other inflows (outflows) of cash	-528.4%	-393.13	93	303
Net Cashflows From Investing Activities	-227.9%	-516.83	-156.9	-181.19
Proceeds from exercise of stock options	-495.7%	0.09	1.23	2.7
Proceeds from borrowings	-	40	0	0
Payments of lease liabilities	70.8%	6.45	4.19	4.61
Dividends paid	37.7%	74	54	54
Interest paid	273.6%	4.96	2.06	1.66
Other inflows (outflows) of cash	-1%	0	0.01	-0.23
Net Cashflows from Financing Activities	21.8%	-46.16	-59.29	-57.96
Net change in cash and cash eq.	87.2%	-7.4	-64.42	-2.56

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	174.1%	75	28	1.9
Change in inventories	144.9%	96	-210.58	-77.19
Depreciation	53.2%	96	63	48
Unrealised forex losses/gains	-329.5%	-1.41	2.05	0.22
Share-based payments	-97.1%	1.47	17	0
Net Cashflows from Operations	1169.8%	801	64	181
Dividends received	0%	-0.03	-0.03	-0.02
Interest received	-5.7%	-3.26	-3.03	-16.66
Income taxes paid (refund)	-69.7%	34	110	78
Other inflows (outflows) of cash	8.3%	-13.17	-14.45	-11.59
Net Cashflows From Operating Activities	1259.6%	750	-63.59	75
Proceeds from sales of PPE	4391.5%	54	2.18	3.05
Purchase of property, plant and equipment	-3.4%	732	758	579
Dividends received	0%	0.03	0.03	0.02
Interest received	11.3%	3.26	3.03	18
Other inflows (outflows) of cash	-537%	-418.48	97	386
Net Cashflows From Investing Activities	-66.7%	-1,093.45	-655.62	-172.37
Proceeds from exercise of stock options	-495.7%	0.09	1.23	2.73
Proceeds from borrowings	-34.1%	491	744	102
Payments of lease liabilities	19.9%	6.6	5.67	6.89
Dividends paid	37.7%	74	54	54
Interest paid	174.1%	75	28	1.9
Other inflows (outflows) of cash	-	0	0	-0.23
Net Cashflows from Financing Activities	-49%	336	658	42
Net change in cash and cash eq.	85.8%	-7.83	-61.27	-56.11

Investor Care
Dividend Yield	0.44%
Dividend/Share (TTM)	20
Shares Dilution (1Y)	0.04%
Diluted EPS (TTM)	53.19

Financial Health
Current Ratio	1.55
Debt/Equity	0.55
Debt/Cashflow	0.55

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	NAVINFLUOR	Chemicals
PE	85.47	53.74
PS	9.83	4.52
Growth	3.9 %	7.3 %

Share Holdings

Understand Navin Fluorine International ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
MAFATLAL IMPEX PRIVATE LIMITED n(Mafatlal Exim Pvt Ltd amalgamated with Mafatlal Impex Pvt Ltd)	26.29%
Other	12.47%
LIFE INSURANCE CORPORATION OF INDIA	9.81%
GOVERNMENT PENSION FUND GLOBAL	3.2%
ICICI PRUDENTIAL MUTUAL FUNDS	3.1%
SBI MUTUAL FUNDS	1.83%
AXIS MUTUAL FUND TRUSTEE LIMITED	1.71%
DSP MUTUAL FUNDS	1.53%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED	1.51%
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY	1.43%
EDELWEISS MUTUAL FUNDS	1.21%
VISHAD PADMANABH MAFATLAL	1.08%
AJAY UPADHYAYA	1.01%
VISHAD MAFATLAL AS TRUSTEE OF VISHAD P MAFATLAL FAMILY TRUST NO. 1	0.77%
VISHAD PADMANABH MAFATLAL PUBLIC CHARITABLE TRUST NO. 1	0.24%
PADMANABH ARVIND MAFATLAL (HUF)t	0.03%
VISHAD P. MAFATLAL PAM HUF1 P MAFATLALt	0.01%
PAMIL INVESTMENTS PVT LTD	0.01%
TEREBINTH VENTURES PRIVATE LIMITED (formerly known as Anshi Ventures Private Limited)	0%
RUPAL VISHAD MAFATLALt	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
PIDILITIND	Pidilite IndustriesSpecialty Chemicals	1.53 LCr	13.12 kCr	+5.58%	+0.69%	77.57	11.67	+6.77%	+14.11%
SRF	SRFSpecialty Chemicals	88.48 kCr	14.07 kCr	+0.11%	+11.84%	77.15	6.29	+4.78%	-22.29%
FLUOROCHEM	Gujarat FluorochemicalsSpecialty Chemicals	42.46 kCr	4.7 kCr	-1.95%	+6.16%	93.11	9.04	+0.35%	-31.52%
AARTIIND	Aarti IndustriesSpecialty Chemicals	15.44 kCr	7.11 kCr	+6.27%	-42.65%	42.08	2.17	+13.53%	-15.30%
GALAXYSURF	Galaxy SurfactantsSpecialty Chemicals	7.31 kCr	4.05 kCr	-8.12%	-19.91%	23.84	1.8	+4.96%	-2.53%

Valuation
Market Cap	22.56 kCr
Price/Earnings (Trailing)	85.47
Price/Sales (Trailing)	9.83
EV/EBITDA	44.29
Price/Free Cashflow	925.99
MarketCap/EBT	67.86

Fundamentals
Revenue (TTM)	2.29 kCr
Rev. Growth (Yr)	20.04%
Rev. Growth (Qtr)	16.42%
Earnings (TTM)	263.99 Cr
Earnings Growth (Yr)	7.15%
Earnings Growth (Qtr)	42.13%

Profitability
Operating Margin	14.49%
EBT Margin	14.49%
Return on Equity	10.69%
Return on Assets	5.94%
Free Cashflow Yield	0.11%

NAVINFLUOR - Navin Fluorine International Limited Share Price

What does Navin Fluorine International Limited do?

Summary of Latest Earnings Report from Navin Fluorine International

Balance Sheet for Navin Fluorine International

Income Statement for Navin Fluorine International

Cash Flow for Navin Fluorine International

Investor Care

Financial Health

Sector Comparison: NAVINFLUOR vs Chemicals & Petrochemicals

Comparative Metrics

Performance Comparison

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Is Navin Fluorine International Better than it's peers?

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Valuation

Fundamentals

Profitability